NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Restricted access

The NCCN Guidelines for Cervical Cancer provide recommendations for diagnostic workup, staging, and treatment of patients with the disease. These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:730.

  • 2.

    Wang SS, Carreon JD, Gomez SL, . Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004. Cancer 2010;116:949956.

  • 3.

    Arbyn M, Weiderpass E, Bruni L, . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8:e191203.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Borcoman E, Le Tourneau C. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol 2017;9:431439.

  • 5.

    Kjær SK, Frederiksen K, Munk C, . Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:14781488.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Rodríguez AC, Schiffman M, Herrero R, . Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315324.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Arbyn M, Xu L, Simoens C, . Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;5:CD009069.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Clifford GM, Smith JS, Plummer M, . Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:6373.

  • 9.

    Tewari KS, Sill MW, Penson RT, . Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:16541663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Kitagawa R, Katsumata N, Shibata T, . Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:21292135.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Oncology Nursing Society. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Accessed May 5, 2020. Available at: https://voice.ons.org/news-and-views/fda-grants-accelerated-approval-to-pembrolizumab-for-first-tissuesite-agnostic

  • 12.

    Frenel JS, Le Tourneau C, O’Neil BH, . Pembrolizumab in patients with advanced cervical squamous cell cancer: preliminary results from the phase Ib KEYNOTE-028 study [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 5515.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Frenel JS, Le Tourneau C, O’Neil B, . Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 2017;35:40354041.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. Accessed May 5, 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-cervical-cancer-disease-progression-during-or-after-chemotherapy

  • 15.

    Chung HC, Schellens JH, Delord JP, . Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 5522.

    • Search Google Scholar
    • Export Citation
  • 16.

    Chung HC, Ros W, Delord JP, . Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:14701478.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Bhatla N, Berek JS, Cuello Fredes M, . Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129135.

  • 18.

    Corrigendum to “Revised FIGO staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 145(2019) 129-135]. Int J Gynaecol Obstet 2019;147:279280.

    • Search Google Scholar
    • Export Citation
  • 19.

    Benedet JL, Bender H, Jones H III, . FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000;70:209262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Zaino RJ. Glandular lesions of the uterine cervix. Mod Pathol 2000;13:261274.

  • 21.

    Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 2002;21:314326.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Diaz De Vivar A, Roma AA, Park KJ, . Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol 2013;32:592601.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Spaans VM, Scheunhage DA, Barzaghi B, . Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: pattern A predicts excellent survival. Gynecol Oncol 2018;151:196201.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Stolnicu S, Barsan I, Hoang L, . Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV. Gynecol Oncol 2018;150:5660.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Stolnicu S, Barsan I, Hoang L, . International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 2018;42:214226.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Roma AA, Mistretta TA, Diaz De Vivar A, . New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome. Gynecol Oncol 2016;141:3642.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1556 1556 1491
PDF Downloads 739 739 720
EPUB Downloads 0 0 0